Kidney-Protection Therapy Gap Scanner
A registry tool that scans a health system's diabetes population, finds patients with diabetic kidney disease who are missing one of the kidney-protective drug classes recommended by the ADA (ACE inhibitor/ARB, SGLT2 inhibitor, finerenone), and hands prescribers a one-click order bundle with the required monitoring labs.
Concept
A population-health module that runs continuously against a health system's diabetes registry and lab feed. For every adult with type 2 diabetes who has both albuminuria (urine albumin-to-creatinine ratio at or above ~30 mg/g) and reduced kidney filtration, it checks the pillars of the ADA's kidney-protection standard: (1) an ACE inhibitor or ARB at maximally tolerated dose, (2) an SGLT2 inhibitor (recommended for albuminuric CKD in type 2 diabetes down to a low eGFR floor), and (3) finerenone for patients already on maximally tolerated RAAS blockade with acceptable potassium. Each missing pillar generates a patient-specific worklist item and a one-click order bundle that includes the baseline and follow-up potassium and creatinine labs these drugs require. A dashboard shows gap rates by clinic and panel so population-health teams chase the biggest gaps first.
Why now
The 2026 ADA Standards of Care chapter on CKD and risk management [0] consolidates a multi-drug kidney-protection standard for albuminuric CKD in type 2 diabetes — RAAS blockade, SGLT2 inhibitors, and finerenone — each with its own eligibility thresholds and lab-monitoring requirements. That is precisely the multi-condition, multi-lab logic that manual chart review misses and a registry rules engine handles well. The chapter is refreshed annually under an explicit evidence-grading system [0], giving the rule set a defined maintenance path. The pharmacologic-treatment chapter [3] reinforces that drug selection in diabetes should be driven by comorbidities such as CKD, supporting prescriber-facing prompts at the moment of therapy selection. The GBD 2023 analysis [5] — covering adults across 204 countries and territories from 1990 to 2023 — documents CKD as among the leading causes of mortality and morbidity and was explicitly built to inform identification and treatment policy, underscoring how much treatable CKD is currently managed suboptimally.
Written by GLM · 13 Oct 2026
AI assessment
A high-utility clinical decision support tool that converts complex ADA guidelines into a concrete, actionable worklist for value-based care providers.
- Evidence strength 5/5
- The idea is directly mapped to the 2026 ADA Standards of Care and supported by GBD 2023 data and existing research on computable phenotypes for CKD.
- Market pull 5/5
- Value-based care entities (like agilon or Strive) have direct financial incentives to prevent dialysis, making this a high-priority tool for risk-contract management.
- Novelty & moat 3/5
- While it shares the 'surveillance' mechanism of the Referral Trigger Engine, it focuses on therapeutic optimization (the 'gap') rather than just referral, filling a distinct clinical need.
- Feasibility 4/5
- The logic is based on deterministic clinical rules (labs and drug lists), making it highly feasible to build as an EHR-integrated module.
- Wedge clarity 5/5
- The 'one-click order bundle' is a sharp, specific wedge that solves the primary friction point for prescribers: the administrative burden of ordering monitoring labs.
- Simplicity / focus 5/5
- The product is a single, focused utility—a gap scanner—rather than an over-scoped platform.
Scored by Gemma 4 · 13 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Business analysis
The PESTEL analysis reveals a strong alignment between clinical guidelines (ADA 2026) and the economic incentives of value-based care, though success depends on overcoming technical EHR integration hurdles and physician alert fatigue. The idea is highly viable because it transforms complex, multi-drug clinical standards into a measurable, actionable operational workflow for risk-bearing entities.
Political2
Economic3
Social2
Technological3
Environmental1
Legal3
The tool's viability depends heavily on evolving ADA clinical standards, healthcare regulations, and the shift toward value-based care contracts. · Generated 2026-10-13 by Gemma 4AI-generatedFull PESTEL Analysis →
Who benefits
- Strive Healthcompany
As a value-based kidney care company, Strive Health bears the cost when patients with type 2 diabetes and CKD progress because they are missing an SGLT2 inhibitor or finerenone; a gap scanner gives its embedded care teams a direct worklist of fixable therapy gaps.
- agilon healthcompany
agilon's Medicare Advantage-focused primary care groups are paid to keep diabetic CKD patients off dialysis; closing SGLT2 inhibitor and finerenone gaps is one of the highest-leverage quality and cost levers available to them.
- Interwell Healthcompany
Interwell's value-based kidney programs depend on finding and optimizing therapy for albuminuric CKD patients across its large nephrologist network; the scanner operationalizes the ADA drug stack as a population dashboard.
- Geisingerorganization
Geisinger runs mature diabetes registries and proactive care-gap outreach; a therapy-gap module fits directly into its existing population-health infrastructure.
- Bayercompany
Bayer makes finerenone (Kerendia), and a large share of guideline-eligible patients are never offered it; a scanner that surfaces eligible-but-untreated patients supports appropriate uptake through its market-access channels.
Research it builds on
- Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023Patrick Barry Mark, Lauryn K Stafford, Morgan Erika Grams et al. · 2025 · 397 citationsAll ideas from this paper →
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 191 citationsAll ideas from this paper →
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 104 citationsAll ideas from this paper →
- Decision Support and CKDAndrew S. Narva · 2012 · 11 citationsAll ideas from this paper →
- Refining Clinical Phenotypes to Improve Clinical Decision Support and Reduce Alert Fatigue: A Feasibility StudyLipika Samal, Edward Wu, Skye Aaron et al. · 2023 · 8 citationsAll ideas from this paper →